PF-Atlas › Clinical Trials › NCT04702360

ELX/TEZ/IVA Expanded Access Program for Cystic Fibrosis Patients With at Least One F508del Mutation

ELX/TEZ/IVA · Not specified

Registry ID
NCT04702360
Phase
Not specified
Status
Approved For Marketing
Drug / intervention
ELX/TEZ/IVA
Sponsor
Vertex Pharmaceuticals Incorporated

About this trial

The purpose of this program is to provide elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) to CF patients in critical need who are 6 to 11 years of age with at least one F508del mutation in response to unsolicited physician requests.

View NCT04702360 on ClinicalTrials.gov →

Explore related

All ELX/TEZ/IVA trialsAll IPF trials

Related trials

ELX/TEZ/IVA — NCT05153317ELX/TEZ/IVA — NCT04545515ELX/TEZ/IVA — NCT05274269ELX/TEZ/IVA — NCT03691779ELX/TEZ/IVA — NCT04362761ELX/TEZ/IVA — NCT04105972
Medical disclaimer. This page summarizes public trial data for NCT04702360 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.